Drug Regeneration Intelligence (DRI) officials search Cipla’s premises, including its Mumbai office and a depot in Bhiwandi, as part of an investigation into the classification of imported pharmaceutical products. Cipla says it is cooperating with authorities and that the searches do not have a material impact on its financials, operations, or other business activities.

Both outlets report the same core event and cite the company’s stance that business continuity is unaffected. The difference is largely in emphasis: The Hindu leads with the specific focus on imported drug classification, while Business Line - Home frames the matter more broadly as a DRI search involving an imported pharma product.

Neither report, based on the provided material, includes details on allegations, timelines beyond the searches, or any outcomes from the investigation. The coverage therefore centres on what the authorities are doing and Cipla’s immediate response.